Clinical trial
Everolimus in Treating Patients With Stage IV Melanoma
NCT00098553 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00098553 |
|---|---|
| Title | Everolimus in Treating Patients With Stage IV Melanoma |
| Official title | Phase II Trial Of RAD-001 In Metastatic Malignant Melanoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | everolimus |
| Enrollment | 53 |
| Start date | Apr 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Feb 1, 2010 |
| First posted | Dec 8, 2004 |
| Last update posted | Jul 6, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: